AstraZeneca in AI collaboration with Immunai to inform cancer ...
WEB1 day ago — AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said ...
Immunai and AstraZeneca's $18 Million AI Collaboration to …
WEB2 days ago — Immunai Inc., a New York-based artificial intelligence (AI) and biotech firm, is collaborating with AstraZeneca. The partnership will provide Immunai with $18 million for its initial phase. This collaboration focuses on enhancing clinical decision-making, including dose selection and biomarker identification. Immunai will leverage its AI immune system model, the IDE, to improve clinical trial ...
Immunai, AstraZeneca collaborate to optimize cancer clinical …
WEBUnder the terms of the agreement, AstraZeneca will leverage Immunai’s platform and machine learning capabilities to inform certain oncology clinical trials.
Israel's Immunai expands strategic tie with AstraZeneca
WEB2 days ago — Israeli company Immunai, a developer of AI-based tools for improving drug discovery processes, has announced a strategic agreement with pharmaceuticals company AstraZeneca. Immunai will receive $18 million from AstraZeneca at the initial stage of the research, but the main significance of the deal is not the initial sum, but the fact that a ...
Israeli AI startup forges $18m partnership with AstraZeneca for …
WEB1 day ago — Israeli-American biotech unicorn Immunai on Thursday secured a $18 million partnership to help the Anglo-Swedish pharma giant AstraZeneca improve the effectiveness and potential success rates of ...
AstraZeneca extends AI immuno-oncology R&D pact with Immunai
WEB1 day ago — AstraZeneca extends AI immuno-oncology R&D pact with Immunai. AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its artificial-intelligence ...
Immunai signs $18M collaboration with AstraZeneca to make …
WEB1 day ago — AstraZeneca. Israeli startup Immunai, which has developed a system that maps the human immune system with single-cell granularity, has announced a multi-year collaboration with AstraZeneca. Under the terms of the agreement, Immunai is set to receive $18 million for the initial phase of the collaboration. The collaboration will …
AstraZeneca in AI collaboration with Immunai to inform cancer …
WEB1 day ago — (Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the ...
Immunai announces collaboration with AstraZeneca for …
WEB1 day ago — Immunai announces collaboration with AstraZeneca for advanced clinical trial optimization. Immunai Inc., a NY-based artificial intelligence and biotech company, mapping the human immune system ...
AstraZeneca in AI Collaboration With Immunai to Inform Cancer …
WEB1 day ago — REUTERS/Johanna Geron/File Photo. (Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain ...
- Some results have been removed